Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
BURLINGTON, Mass., March 03, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
- Raymond James 38th Annual Institutional Investors Conference
Dr. Clayman will present on Tuesday, March 7, 2017 at 7:30 a.m. EST
- Cowen & Company 37th Annual Health Care Conference
Dr. Clayman will present on Wednesday, March 8, 2017 at 8:00 a.m. EST
To access the live webcast and subsequent archived recordings for the presentations, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, ZilrettaTM (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contacts: Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected] Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
